1. Home
  2. ICUI vs ARQT Comparison

ICUI vs ARQT Comparison

Compare ICUI & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ICU Medical Inc.

ICUI

ICU Medical Inc.

HOLD

Current Price

$146.10

Market Cap

3.9B

Sector

Health Care

ML Signal

HOLD

Logo Arcutis Biotherapeutics Inc.

ARQT

Arcutis Biotherapeutics Inc.

HOLD

Current Price

$25.00

Market Cap

3.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ICUI
ARQT
Founded
1984
2016
Country
United States
United States
Employees
N/A
342
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.9B
3.3B
IPO Year
1995
2020

Fundamental Metrics

Financial Performance
Metric
ICUI
ARQT
Price
$146.10
$25.00
Analyst Decision
Buy
Strong Buy
Analyst Count
5
7
Target Price
$182.25
$32.14
AVG Volume (30 Days)
272.9K
1.2M
Earning Date
05-22-2026
05-25-2026
Dividend Yield
N/A
N/A
EPS Growth
100.62
88.79
EPS
0.03
N/A
Revenue
$2,231,262,000.00
$376,072,000.00
Revenue This Year
N/A
$26.91
Revenue Next Year
$4.10
$30.59
P/E Ratio
$4,973.67
N/A
Revenue Growth
N/A
91.34
52 Week Low
$107.02
$11.86
52 Week High
$160.29
$31.77

Technical Indicators

Market Signals
Indicator
ICUI
ARQT
Relative Strength Index (RSI) 44.65 42.02
Support Level $142.11 $24.81
Resistance Level $151.64 $27.26
Average True Range (ATR) 6.67 1.52
MACD -0.34 -0.00
Stochastic Oscillator 28.86 7.59

Price Performance

Historical Comparison
ICUI
ARQT

About ICUI ICU Medical Inc.

ICU Medical is a California-based pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. ICU has become one of the largest players in its industry following its acquisition of Hospira Infusion Systems from Pfizer in 2017 and Smiths Medical from Smiths Group in 2022. It holds top-tier positions across its three reporting segments: consumables (50% of consolidated revenue), infusion systems (30%), and vital care (20%). The combined entity remains primarily US-focused, generating over 60% of its sales domestically.

About ARQT Arcutis Biotherapeutics Inc.

Arcutis Biotherapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its current portfolio is comprised of differentiated topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. The Company has one reportable segment relating to the development and commercialization of treatments for dermatological diseases.

Share on Social Networks: